Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis-Reference-Cited by-同舟云学术

Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis

Published:2019-11-28 Issue:2 Volume:23 Page:349-355
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Malouff Timothy D.,Stross William C.^ORCID,Seneviratne Danushka S.,Waddle Mark R.,May Byron C.,Buskirk Steven J.,Tzou Katherine S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-019-0191-9.pdf

Reference28 articles.

1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8:a030361.

2. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER cancer statistics review 1975–2013. Bethesda, MD: National Cancer Institute; 2016.

3. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17–24.

4. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43–54.

5. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1061–9.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrafractional motion and dosimetric analysis in prostate stereotactic body radiation therapy with auto beam hold technique;Biomedical Physics & Engineering Express;2024-06-26

2. Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer;Scientific Reports;2024-06-19

3. Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer;International Journal of Particle Therapy;2024-06

4. Simulating an intra-fraction adaptive workflow to enable PTV margin reduction in MRIgART volumetric modulated arc therapy for prostate SBRT;Frontiers in Oncology;2024-01-08

5. When Patience is a Failing: The Case for Patient Reported Outcomes Adoption;International Journal of Radiation Oncology*Biology*Physics;2023-07